These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 9636447)

  • 1. Cytolytic induction therapy in heart and lung transplantation: the protagonist opinion.
    Wahlers T
    Transplant Proc; 1998 Jun; 30(4):1100-3. PubMed ID: 9636447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tacrolimus (FK506) proves superior to OKT3 for treating episodes of persistent rejection following intrathoracic transplantation.
    Meiser BM; Uberfuhr P; Schulze C; Fuchs A; Mair H; Reichenspurner H; Kreuzer E; Reichart B
    Transplant Proc; 1997; 29(1-2):605-6. PubMed ID: 9123150
    [No Abstract]   [Full Text] [Related]  

  • 3. Induction immunosuppression with OKT3 monoclonal antibody in cardiac transplant recipients.
    Pulpón LA; Domínguez P; Cháfer M; Segovia J; Crespo MG; Pradas G; Burgos R; Figuera D
    Transplant Proc; 1990 Oct; 22(5):2319. PubMed ID: 2120816
    [No Abstract]   [Full Text] [Related]  

  • 4. Induction therapy in cardiac transplantation: when and why?
    Baran DA
    Heart Fail Clin; 2007 Jan; 3(1):31-41. PubMed ID: 17545007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies of immunosuppression in cardiac transplantation.
    Renlund DG; O'Connell JB; Bristow MR
    Semin Thorac Cardiovasc Surg; 1990 Apr; 2(2):181-8. PubMed ID: 2127901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nursing implications of immunosuppression in transplantation.
    Shaefer M; Williams L
    Nurs Clin North Am; 1991 Jun; 26(2):291-314. PubMed ID: 1904575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Annual review of transplantation.
    First MR
    Clin Transpl; 1990; ():357-73. PubMed ID: 2129410
    [No Abstract]   [Full Text] [Related]  

  • 8. Early rejection prophylaxis in heart transplantation: is cytolytic therapy necessary?
    Renlund DG; O'Connell JB; Bristow MR
    J Heart Transplant; 1989; 8(3):191-3. PubMed ID: 2661767
    [No Abstract]   [Full Text] [Related]  

  • 9. Antilymphocyte-antibody prophylaxis: review of the adult experience in heart transplantation.
    Taylor DO; Kfoury AG; Pisani B; Hammond EH; Renlund DG
    Transplant Proc; 1997 Dec; 29(8A):13S-15S. PubMed ID: 9414668
    [No Abstract]   [Full Text] [Related]  

  • 10. Pancreas transplantation with ATG vs OKT3.
    Rosenberg L
    Transplant Proc; 1997 Nov; 29(7A):35S-36S. PubMed ID: 9366927
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunosuppressive T-cell antibody induction for heart transplant recipients.
    Penninga L; Møller CH; Gustafsson F; Gluud C; Steinbrüchel DA
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008842. PubMed ID: 24297433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed development of obliterative bronchiolitis syndrome with OKT3 after unilateral lung transplantation. A plea for multicenter immunosuppressive trials.
    Ross DJ; Jordan SC; Nathan SD; Kass RM; Koerner SK
    Chest; 1996 Apr; 109(4):870-3. PubMed ID: 8635362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction immunosuppression in kidney transplant recipients older than 60 years of age : safety and efficacy of ATGAM, OKT3 and Simulect.
    Heifets M; Saeed MI; Parikh MH; Sierka D; Kumar MS
    Drugs Aging; 2004; 21(11):747-56. PubMed ID: 15323580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of immunosuppression with OKT3 following heart transplantation: kidney function as a criterion for control of protocol duration.
    Rodríguez JA; Crespo-Leiro MG; Paniagua MJ; Muñiz J; Hermida LF; Fojón S; Cuenca JJ; Juffé-Stein A; Castro-Beiras A
    Transplant Proc; 1999 Sep; 31(6):2517-8. PubMed ID: 10500696
    [No Abstract]   [Full Text] [Related]  

  • 15. To induce or not to induce: do patients at greatest risk for fatal rejection benefit from cytolytic induction therapy?
    Higgins R; Kirklin JK; Brown RN; Rayburn BK; Wagoner L; Oren R; Miller L; Flattery M; Bourge RC;
    J Heart Lung Transplant; 2005 Apr; 24(4):392-400. PubMed ID: 15797738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter evaluation of immunosuppressive regimens in heart transplantation. The Collaborative Transplant Study.
    Opelz G
    Transplant Proc; 1997; 29(1-2):617-9. PubMed ID: 9123156
    [No Abstract]   [Full Text] [Related]  

  • 17. Induction immunosuppression.
    Kirk AD
    Transplantation; 2006 Sep; 82(5):593-602. PubMed ID: 16969280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal versus polyclonal antibody therapy for prophylaxis against rejection after heart transplantation.
    Kormos RL; Herlan DB; Armitage JM; Stein K; Kaufman C; Zeevi A; Duquesnoy R; Hardesty RL; Griffith BP
    J Heart Transplant; 1990; 9(1):1-9, discussion 9-10. PubMed ID: 2107288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tacrolimus (FK 506) in clinical cardiac transplantation: a five-year experience.
    Pham SM; Kormos RL; Kawai A; Murali S; Hattler BG; Demetris AJ; Griffith BP
    Transplant Proc; 1996 Apr; 28(2):1002-4. PubMed ID: 8623208
    [No Abstract]   [Full Text] [Related]  

  • 20. Medium-term outcome of tacrolimus immunosuppression following rejection or graft dysfunction in heart transplant patients.
    Marcus N; Khaghani A; Burke M; Yacoub M; Banner N
    Transplant Proc; 1998 Jun; 30(4):1134-5. PubMed ID: 9636460
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.